Research progress of salivary glands injury secondary to 225Ac/ 177Lu-PSMA-617 in the treatment of prostate cancer and its protection

VernacularTitle:225Ac/ 177Lu-PSMA-617治疗前列腺癌继发唾液腺损伤及保护的研究进展
Author: Wenhui FU ¹ ; Tingting XU ; Huipan LIU ; Xinyi ZHANG ; Chengrun ZENG ; Yue CHEN
Author Information

1. 西南医科大学附属医院核医学科、核医学与分子影像四川省重点实验室、四川省院士（专家）工作站，泸州　646000
Keywords: Prostatic neoplasms; Salivary glands; Prostate-specific membrane antigen; Radiotherapy; Actinium; Lutetium; Trends
From: Chinese Journal of Nuclear Medicine and Molecular Imaging 2022;42(10):628-632
CountryChina
Language:Chinese
Abstract: Prostate specific membrane antigen (PSMA) radioligand therapy (RLT) is effective in metastatic castration-resistant prostate cancer (mCRPC). However, PSMA RLT can cause radiation damage to salivary glands, especially 225Ac/ 177Lu-PSMA-617. Radiation-related salivary glands damage can cause xerostomia, reduce the quality of life, and even limit the dose of radiopharmaceuticals and reduce the efficacy of tumor treatment. At present, there are few literatures on PSMA RLT related salivary glands damage in China. In this article, radiation-related salivary glands damage and the related protective measures during 225Ac/ 177Lu-PSMA-617 RLT are reviewed based on domestic and foreign studies.